In breast cancer treatment, Navitoclax has been proven to enhance the effectiveness of epidermal growth factor receptor (EGFR)-targeted antibody-drug conjugates for TNBC treatment in animal experiments. This evidence concerns the gene EGFR and breast carcinoma.